CRSP (CRISPR Therapeutics AG) Research & Development: $377.15 Mil (TTM As of Mar. 2026)


CRSP CRISPR Therapeutics AG CRSP
41 GF Score
Price $53.55
GF Value $2.42
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Research & Development?

CRISPR Therapeutics AG CRSP -0.81% 41 Research & Development is $377.15 Mil as of Mar. 2026. GuruFocus rates CRSP with a GF Score™ of 41/100 and a GF Value™ of $2.42 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. CRISPR Therapeutics AG's Research & Development for the three months ended in Mar. 2026 was $68.57 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $377.15 Mil.

CRISPR Therapeutics AG  (NAS:CRSP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CRISPR Therapeutics AG Research & Development Related Terms

CRISPR Therapeutics AG Research & Development Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Research & Development Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 340.57 461.65 387.33 310.24 381.06

CRISPR Therapeutics AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.48 166.15 58.90 83.53 68.57
CRSP
41GF Score
CRISPR Therapeutics AG CRSP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $377.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $377.15 Mil mean?
CRISPR Therapeutics AG (CRSP) has a Research & Development of $377.15 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Research & Development too high?
CRISPR Therapeutics AG's current Research & Development is $377.15 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Research & Development compare to CGON and XENE?
CRISPR Therapeutics AG's Research & Development of $377.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Research & Development is $377.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.42, compared to a current price of $53.55 — trading 2112.8% above its estimated fair value. The current Research & Development is $377.15 Mil. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Research & Development is $377.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $53.55 is trading 2112.8% above its estimated GF Value™ of $2.42. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for CRSP:

  • Research & Development: $377.15 Mil
  • GF Value™: $2.42 vs. price of $53.55 (2112.8% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score

Get the complete analysis for CRSP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.55
Price
$2.42
GF Value